Efficiency of citicoline in the therapy of cognitive and motor disorders in patients in the early recovery period of stroke


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a critical review of studies of citicoline in the treatment of cognitive disorders after stroke and chronic cerebral ischemia, as well as in the treatment of post-stroke motor disorders in the early recovery period after acute cerebrovascular events. The results of these studies indicate that citicoLine can be considered one of the most studied neuroprotective drugs. Due to the fact that citicoline can affect different stages of ischemic damage in clinical practice the drug shows effect in acute stroke and in the rehabilitation phase, thus stimulating the recovery of both cognitive and motor functions.

Full Text

Restricted Access

About the authors

Maksim Alekseevich Domashenko

S.P. Botkin City clinical hospital

Email: mdomashenko@gmail.com
PhD, head of the Regional vascular center

Dmitriy Vladimirovich Sergeev

Research center of neurology

PhD, neurologist

References

  1. Jauch E.C., Saver J.L., Adams H.P. Jr, Bruno A., Connors J.J., Demaerschalk B.M., Khatri P., McMullan P.W. Jr, Qureshi A.I., Rosenfield K., Scott P.A., Summers D.R., Wang D.Z., Wintermark M., Yonas H. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2013;44:870-947.
  2. Emberson J., Lees K.R., Lyden P., Blackwell L., Albers G., Bluhmki E., Brott T., Cohen G., Davis S., Donnan G., Grotta J., Howard G., Kaste M., Koga M., von Kummer R., Lansberg M., Lindley R.I., Murray G., Olivot J.M., Parsons M., Tilley B., Toni D., Toyoda K., Wahlgren N., Wardlaw J., Whiteley W., del Zoppo G.J., Baigent C., Sandercock P., Hacke W. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929-35.
  3. Powers W.J., Derdeyn C.P., Biller J. Coffey C.S., Hoh B.L., Jauch E.C., Johnston K.C., Johnston S.C., Khalessi A.A., Kidwell C.S., Meschia J.F., Ovbiagele B., Yavagal D.R.; American Heart Association Stroke Council. American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare profession- als from the American Heart Association/American Stroke Association. Stroke. 2015;46:3020-35.
  4. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008/2009. Материалы сайта http://www.eso-stroke.org/recommendations.
  5. Kernan W.N., Ovbiagele B., Black H.R., Bravata D.M., Chimowitz M.I., Ezekowitz M.D., Fang M.C., Fisher M., Furie K.L., Heck D.V., Johnston S.C., Kasner S.E., Kittner S.J., Mitchell P.H., Rich M.W., Richardson D., Schwamm L.H., Wilson J.A. Guidelines for the prevention of stroke in patients with stroke and transient ischemick attack. A Guideline for healthcare prifessionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-236.
  6. Ginsberg M.D. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008;55(3):363-9.
  7. Grupke S., Hall J., Dobbs M., Bix G.J., Fraser J.F. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview. Clin. Neurol. Neurosurg. 2015;129:1-9.
  8. Bustamante A., Giralt D., Garcia-Bonilla L., Campos M., Rosell A., Montaner J. Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J. Neurochem. 2012;1 23(2):217-25.
  9. Gutierrez-Fernandez M., Rodriguez-Frutos B., Fuentes B., Vallejo-Cremades M.T., Alvarez-Grech J., Expbsito-Alcaide M., Diez-Tejedor E. CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem. Int. 2012;60:310-7.
  10. Пирадов М.А., Сергеев Д.В., Кротенкова М.В. Применение цераксона в остром периоде полушарного ишемического инсульта: клиническая и КТ-перфузионная оценка. Анналы клинической и экспериментальной неврологии. 2012;3:31-6. [Piradov M.A., Sergeev D.V., Krotenkova M.V. Application of ceraxon in the acute period of hemispheric ischemic stroke: clinical and CT perfusion assessment. Annals of clinical and experimental neurology. 2012;3:31-6 (in Russian)]
  11. Secades J. Citicoline: pharmacological and clinical review, 2010 update. Rev. Neurol. 2011;52(Suppl. 2):S1-S62.
  12. Secades J., Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp. Clin. Pharmacol. 1995;17(Suppl. B):1-54.
  13. Домашенко М.А., Максимова М.Ю., Сергеев Д.В., Пирадов М.А. Цитиколин в лечении ишемических нарушений мозгового кровообращения. РМЖ. 2013;30:1540-2. [Domashenko M.A., Maksimova M.Yu., Sergeev D.V., Piradov A.M. Citicoline in the treatment of ischemic disorders of cerebral circulation. Russian medical journal. 2013;30:1540-2 (in Russian)]
  14. Secades J.J., Alvarez-Sabin J., Castillo J., Diez-Tejedor E., Martinez-Vila E., Rios J., Oudovenko N. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J. Stroke Cerebrovasc. Dis. 2016;25(8):1984-96.
  15. Secades J. Citicoline for the treatment of head injury: a systematic review and meta-analysis of controlled clinical trials. J. Trauma Treat. 2014;4(1):227.
  16. Grieb P. Citicoline: a food that may improve memory. Med. Sci. Rev. 2015;2:67-72.
  17. Watanabe S., Kono S., Nakashima Y., Mitsunobu K., Otsuki S. Effects of various cerebral metabolic activators on glucose metabolism of brain. Folia Psychiatr. Neurol. Jpn. 1975;29:67-76.
  18. Martinet M., Fonlupt P., Pacheco H. Effects of cytidine-5' diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch. Int. Pharmacodyn. Ther. 1973;239:52-61.
  19. Hurtado O., Cardenas A., Pradillo J.M., Morales J.R., Ortego F., Sobrino T., Castillo J., Moro M.A., Lizasoain I. A chronic treatment with CDPcholine improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol. Dis. 2007;26:105-1 1.
  20. Tham W., Auchus A.P., Thong M., Goh M.L., Chang H.M., Wong M.C., Chen C.P. Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J. Neurol. Sci. 2002;203-204:49-52.
  21. Madureira S., Guerreiro M., Ferro J.M. Dementia and cognitive impairment three months after stroke. Eur. J. Neurol. 2001;8:621-7.
  22. Jaillard A., Grand S., François Le Bas J., Hommel M. Predicting cognitive disfunctioning in nondemented patients early after stroke. Cerebrovasc. Dis. 2010;29:415-23.
  23. Reitz C., Bos M.J., Hofman A., Koudstaal P.J., Breteler M.M. Prestroke cognitive performance, incident stroke, and risk of dementia. The Rotterdam study. Stroke. 2008;39:36-41.
  24. Alvarez-Sabin J., Roman G.C. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42(Suppl. 1):S40-3.
  25. Lozano R., Fernandez M.V., Balague A. Alteraciones neuropsiquicas del anciano: evolucion tras la administracion de CDP-colina (citicolina). Med. Clin. (Barc). 1986;87 (Suppl. 1):S30-3.
  26. Chandra B. Treatment of multi-infarct dementia with citicholine. J. Stroke Cerebrovasc. Dis. 1992;2:232-3.
  27. Fioravanti M., Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly Cochrane Database Syst. Rev. 2005;2:CD000269.
  28. Путилина М.В. Особенности комбинированной нейропротекторной терапии острых нарушений мозгового кровообращения. РМЖ. 2009;4:261-7. [Putilina M.V. Features of combination neuroprotective therapy of acute disorders of cerebral circulation. Russian medical journal. 2009;4:261-7 (in Russian)]
  29. Alvarez-Sabin L., Ortega G., Jacas C., Santamarina E., Maisterra O., Ribo M., Molina C., Quintana M., Roman G.C. Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc. Dis. 2013;35(2):146-54.
  30. Alvarez-Sabin J., Santamaria E., Maisterra O., Jacas C., Molina C., Quintana M. Long-term treatment with citicoline prevents cognitive decline and predicts quality of life after first ischemic stroke. Int. J. Molecular Sci. 2016;17(3):390.
  31. Cotroneo A.M., Castagna A., Putignano P., Lacava R., Fanto F., Monteleone F., Rocca F., Malara A., Gareri P. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin. Interv. Aging. 2013;8:131-7.
  32. Secades J.J. Probably role of citicoline in stroke rehabilitation: review of the literature. Rev. Neurol. 2012;54(3):173-9.
  33. Flazama T., Hasegawa T., Ueda S., Sakuma A. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial. Assessed by a new rating scale for recovery in hemiplegia. Int. J. Neurosci. 1980;11(3):211-25.
  34. Ueda S., Hasegawa T., Ando K., et al. Evaluation of the pharmacological effect of CDP-choline injection in post-stroke hemiplegia. Double-blind comparative study using the Hemiplegia Function Test (12-grade evaluation method). Strides of Medicine. 1994;170:297-314.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies